Ovary-ecstatic: Gameto’s Mission to Revive Reproduction
summary
Company builds a stem-cell-derived organoid of the human reproductive system and uses that platform to derive therapeutics; first program, Fertilo IVF/egg-freezing biologic, acts in vitro to make egg retrieval shorter, safer and cheaper and skirts longer patient trials with easier regulation. Platform is developed with a Harvard lab, targets a large IVF market (egg-freezing costs ~$20–30k, used in ~7% of US cycles), and rests on the claim that the ovary ages up to five times faster than other organs.
AI-written summary · about
chapters (10)
- 0:00Introduction to female aging
- 1:08Biological clock challenges
- 3:56Lack of research in health
- 5:51Cell engineering innovation
- 7:26Transitioning to preventative
- 9:57Focus on reproductive longevity
- 12:57Gameto development pipeline
- 16:02Lessons in entrepreneurship
- 17:15Consumerization of healthcare
- 18:47Empowering women with choice